Can neoadjuvant chemotherapy be replaced with immune checkpoint blockade combined with dual anti-HER2 antibodies for HER2-enriched breast cancer?

Translational Breast Cancer Research 2026 Open access

Read full text

Authors: Harry D. Bear

DOI: 10.21037/tbcr-25-57

Cited by: 0

Fields of Study & Subjects

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Cancer Immunotherapy and Biomarkers